Dataset Information

Transcriptome analysis of cultured human pulmonary artery smooth muscle cells (hPASMCs) to explore functional roles for CD26/DPP4 in stimulation with TGF-β1

ABSTRACT: The purpose of this study was to evaluate the role of CD26/DPP4 in hPASMCs in response to TGF-β1. In experimental methods, hPASMCs were treated as follows. The hPASMCs were cultured in Smooth Muscle Cell Growth Medium 2 with 10% fetal bovine serum and were incubated at 37 ℃ in a 5% CO2 incubator. The cells at passage 6 were used for all experiments. The PASMCs were treated with CD26/DPP4 siRNA or non-specific control siRNA for 48 hours, then stimulated with TGF-β1 or PBS for 24 hours. Transcriptome analysis revealed that TGFβ treatment in cultured hPASMCs upregu-lated genes related to pulmonary vascular SMC proliferation, involving the Notch, PI3K-Akt, and NFκB signaling pathways.Conversely, DPP4-siRNA treatment in cultured hPASMCs downregulated these pathways.

ORGANISM(S): Homo sapiens

PROVIDER: GSE248794 | GEO | 2024/01/03

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:CAR T cell therapy has revolutionized the treatment of hematologic malignancies, but its efficacy in solid tumors remains limited due to the immunosuppressive nature of the tumor microenvironment and the inability of T cells to persist and traffic to the tumor site. While current strategies focus on enhancing CAR T cell activity through costimulatory molecules and cytokines, a critical yet often overlooked factor is the competition for nutrients between tumor cells and T cells in the nutrient-deprived tumor microenvironment. To address this challenge, we employed a selective metabolic refueling (MR) strategy by providing T cells with inosine as an alternative fuel source for growth and functionality. In this study, we engineered CAR T cells to co-express a membrane-bound CD26 and a cytoplasmic adenosine deaminase 1 (ADA1) fused to an anti-CD3 scFv. ADA1 irreversibly converts both intracellular and extracellular adenosine to inosine, overcoming adenosine-mediated immunosuppression and providing T cells with inosine for growth. The inclusion of an anti-CD3 scFv fusion partner and overexpressing CD26 boosts ADA1 capture in a membrane proximal manner, providing inosine for T cells and minimizing feeding the tumor cells. We demonstrate that ADA1 is conditionally secreted in an autocrine manner in response to CD3/CD26 stimulation and that it activates CAR T cells through trans-signaling in a tumor-specific manner. In addition, we show that, compared to unmodified CAR T cells, CD26-overexpressing CAR T cells have better migration capacity and are less susceptible to TGF-β1 suppression. Finally, we demonstrate that, in mice models of human hepatocellular carcinoma (GPC3-MR-CAR) and human non-small cell lung cancer (HER2-MR-CAR), metabolically refueled CAR T cells (MR-CAR) are more efficient in reducing tumor growth than unmodified CAR T cells. Thus, selective refueling CAR T cells using ADA1 and CD26 holds promise for improving the efficacy of CAR T cell therapy of solid tumors.

Project description:Different naïve or memory cell subpopulations (i.e., central memory/CM, effector memory/EM, or terminally differentiated effector memory/EMRA) are involved in asthma development, and they display variable levels of the CD26 (dipeptidyl peptidase 4/DPP4). The phenotype and/or severity of the disease could drive to a phenotypic shift in naïve/memory lymphocyte subsets. Therefore, the aim of our work was to evaluate the association of the phenotype and severity of asthma with the relative frequency of CD26-/lo, CD26int, and CD26hi subsets within CD4+ effector T cells (Teff), total CD4- lymphocytes, γδ-T cells, NK cells, and NKT cells. For that, flow cytometry analyses were performed in peripheral blood samples from healthy donors (N=30) and asthma patients (N=119) with different phenotypes/severities. To avoid a priori bias, we have performed a K-means clustering analysis including clinical and flow cytometry data, resulting in four groups, two of them with opposite inflammatory profiles (eosinophilic vs. neutrophilic). CD4-CD26hi cells were reduced in neutrophilic asthma, and negatively correlated with degree of systemic inflammation. Interestingly, the eosinophilic group displayed a general expansion of CD26-/lo lymphocyte subsets. The expansion of CD4+CD26-/lo Teff cells with a TEM/TEMRA phenotype was confirmed in asthma, especially in atopic patients. Further characterisation of this subset by LC MS/MS revealed upregulated levels of innate (e.g., MPO and RNASE2) and cytoskeleton/extracellular matrix (e.g., MMP9, ACTN1) proteins, which matches its terminally differentiated phenotype. Validation by immunofluorescence confirmed the presence of many of these proteins in CD4+ T cells, as well as an enrichment in “flower-like” nuclei and MMP9/RNASE2 levels in CD4+CD26-/lo Teff compared to CD4+ T lymphocytes. Therefore, there is an association between CD26 levels in different lymphocyte subsets and asthma phenotypes/severities. CD4+CD26-/loTEMRA cells expressing innate proteins specific to eosinophils/neutrophils could be relevant in sustaining long-term inflammation in adult allergic asthma.

Dataset Information

Transcriptome analysis of cultured human pulmonary artery smooth muscle cells (hPASMCs) to explore functional roles for CD26/DPP4 in stimulation with TGF-β1

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets